Larkspur Biosciences

Larkspur Biosciences is a Cambridge, Massachusetts precision-oncology company building first-in-class small molecule protein degraders that attack cancer cells where they are most vulnerable. Using its machine-learning-enabled LarkX platform to pinpoint 'cancer cell fitness' genes, Larkspur designs drugs that trigger tumor-intrinsic cell death and disrupt how cancers hide from the immune system. Its lead candidate, LRK-4189, degrades the lipid kinase PIP4K2C and entered first-in-human Phase 1 testing in December 2025 for microsatellite stable colorectal cancer.